SPRO— AI Stock Forecast & Price Targets
Published 7/15/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live SPRO price forecast →
Spero Therapeutics just crashed ~20% in 24h and ~37% over the past month, but the drop coincides with a transformative pivot: FDA approval of Utebzi (tebipenem), a $105M non-dilutive royalty deal with HealthCare Royalty/KKR, and an in-license of Innovent's CD40L antibody IBI355/SP001 for up to $1.1B in milestones. Fundamentals are unusually clean for a micro-cap biotech (net cash, $56M cash vs $2.5M debt, TTM profit from milestone recognition), but the sell-off reflects dilution/execution fears around the Innovent deal and a shift back to clinical-stage cash burn. At $1.70 with an analyst target of $4.00 and RSI 28, risk/reward skews favorably for patient capital, but near-term technicals remain broken.
Do not chase into the Aug 11 earnings print (~27 days away) — that will be the first management commentary on the Innovent deal economics and is binary. Preferred setup: wait for a confirmed bounce off the $1.67 low or a re-test that holds with declining volume; scale-in only 1/3 position sub-$1.75 with a hard stop under $1.55 (below the 52w low gap). Given RSI 28 and 11x relative volume, an oversold bounce toward $2.00-2.10 gap-fill is plausible but should be treated as a trade, not the thesis. Invalidation: close below $1.55 on volume, or negative pre-earnings 8-K.
1-6 month thesis is a re-rating as the market digests that Utebzi royalties are locked in ($105M upfront alone approaches current $98M market cap), and SP001 Phase 2 initiation provides an immunology optionality catalyst. Analyst target is $4.00 (+135%); a realistic base case is $2.50-3.00 as the stock reclaims SMA200 once the deal shock fades. Catalysts: Q2 earnings (Aug 11), SP001 Phase 2 start details, Utebzi commercial launch data from GSK. What would change my mind: any equity raise announcement (would signal the royalty deal was insufficient), SP001 clinical setback, or Utebzi sales miss.
1-3 year thesis hinges entirely on SP001: if IBI355 delivers Phase 2 proof-of-concept in an autoimmune indication, Spero re-rates as a small-cap immunology story with a partnered anti-infective royalty stream underneath — a multi-bagger setup from $1.70. If SP001 fails, the terminal value collapses to Utebzi royalties minus the KKR obligation, likely sub-$1. Structural risk is that a 25-person company is taking on a $1.1B milestone commitment on an early-stage asset from a Chinese biotech — execution and capital requirements will dwarf current resources. This is a binary long-term outcome; size accordingly.
The snapshot is unusual for a micro-cap biotech: TTM revenue $61.2M, TTM profit margin 27.8%, ROE 35.1%, ROIC 28.5%, current ratio 10.5, and debt/equity 0.05 — but these metrics are distorted by a $39.7M Q4'25 milestone-driven revenue print (op income $31.4M) tied to GSK/Utebzi progress. Q1'26 reverted to reality: revenue just $258K and an operating loss of $7.5M, with Q/Q sales down 94.95%. The balance sheet is the real story — $56.1M cash, $2.5M debt, $52.1M working capital, and now a fresh $105M non-recourse royalty financing from HCRx/KKR that monetizes future Utebzi royalties without dilution. That effectively extends runway through the SP001 Phase 2 without a raise, which is critical given only 25 employees and a forward EPS of -$1.11 (forward P/E -1.53 confirms return to burn). Capital allocation is aggressive: management is redeploying Utebzi economics into a swing-for-the-fences immunology bet (SP001 upfront + up to $1.1B milestones to Innovent). Quality of earnings is low (milestone lumpiness), but the funding structure is best-in-class for a company this size.
Every timeframe is broken. On the 1wk chart the stock is down ~88% over 5 years and sits near multi-year lows. The daily shows a clean uptrend from Feb–Jun ($2.10 → $3.00) fully retraced, with a violent gap down from ~$2.15 to $1.70 on the July 14 news — closing below the entire consolidation range and printing a 52-week low of $1.67. RSI(14) at 28.5 is oversold; price sits -23% below SMA20, -32% below SMA50, -29% below SMA200 — capitulation-grade extension. Relative volume of 11.37x confirms forced selling. The Kronos forecast bands are bullish across all timeframes ($2.15 on 1d/daily, $2.46 on 4h, $2.69 on 1h), but the model's realized 1d directional accuracy (59%) is BELOW the 77% naive baseline, and 1wk (83% vs 100%) is also beaten by naive — so heavily discount the yellow bands. Key levels: support $1.67 (52w low) then psychological $1.50; resistance $2.10-2.20 (prior range floor now ceiling), then $2.45 gap-fill zone.
The signal-to-noise ratio in the news is high and mostly constructive despite the tape. Three linked July 14 catalysts: (1) FDA approval of Utebzi (tebipenem pivoxil) — a first-in-class oral carbapenem for cUTI partnered with GSK, which triggers royalty economics; (2) a $105M non-recourse, non-dilutive royalty financing with HealthCare Royalty (KKR affiliate) monetizing those future royalties; (3) an ex-China global license from Innovent for IBI355/SP001, a CD40L antibody entering Phase 2 in immunology, with up to $1.1B in milestones payable by Spero. The 8-K filed under Items 1.01/2.03/7.01/8.01 confirms material long-term obligations. The market clearly read the combination as 'Spero just sold its cash cow to bet on an unproven Phase 2 asset,' hence the -20% day. Seeking Alpha's 'Buy' framing and the pivot to immunology are the bull narrative. The L1 short-float uptick (4.3% → 6.7%) confirms a growing bear thesis; stocktwits sentiment is 100% bullish among tagged messages, which is contrarian-negative in a retail micro-cap.
- SP001 (IBI355) CD40L antibody — Phase 2 immunology development funded by the $105M HCRx royalty monetization; up to $1.1B in milestones payable to Innovent signals large indication ambition
- Utebzi (tebipenem HBr) — FDA-approved first-in-class oral carbapenem for cUTI, commercialized by GSK; royalty stream now partially monetized upfront but residual economics remain
- Second Phase 3 trial for tebipenem completed — supports label expansion and international partnerships (Meiji Seika in Japan, Everest Medicines in Greater China/SE Asia)
- SPR206 — polymyxin-class IV antibiotic for MDR Gram-negative infections, out-licensed to Everest for Asia; potential milestone/royalty layer
- Non-dilutive $105M royalty deal with KKR-backed HCRx extends runway meaningfully without shareholder dilution — a rare structure for a $98M-cap biotech
- SP001 is Phase 2 — high clinical failure rate for CD40L antibodies historically (thrombosis risk in prior programs); a setback would be terminal for the thesis
- $1.1B milestone obligation to Innovent vs. 25 employees and $56M cash — execution and funding gap will likely require future capital raises despite the KKR deal
- Utebzi economics now partially pre-sold to HCRx via non-recourse royalty — caps upside from the anti-infective franchise
- Short float rose 4.3% → 6.7% in 45 days (L1 bearish signal); institutional ownership only 14.5% — thin conviction from smart money
- Q1'26 revenue collapsed to $258K (-95% Q/Q) confirming the business is back to burn mode ex-milestones; forward EPS -$1.11
- Aug 11 earnings is a binary near-term catalyst; management commentary on deal financing could disappoint
- Micro-cap ($98M) with 11.37x relative volume selling and price below all major SMAs — technical damage takes months to repair
- Kronos forecast model has been beaten by the naive baseline at both 1d and 1wk horizons — the bullish yellow bands should not be relied on
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord